Ramucirumab Suppliers & Bulk Manufacturers
Available Forms: Solutions for disinfection
Available Strengths: 100 mg/10 mL
Reference Brands: Cyramza (USA/India)
Category:
Oncology Cancer Care
Ramucirumab is available in Solutions for disinfection
and strengths such as 100 mg/10 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ramucirumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ramucirumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Gastric cancer, also known as stomach cancer, is one of the most common malignancies affecting people worldwide. It ranks among the leading cancers in both men and women, with significant prevalence in regions such as East Asia, parts of Europe, and Latin America. Countries like Japan, China, and several areas in Southern and Eastern Europe report higher rates of this disease, making it an important global health concern. Differences in lifestyle, diet, environmental factors, and genetics are believed to contribute to the variation in incidence across different populations.
In the United States, gastric cancer occurs less frequently compared to some other regions, but certain populations show higher diagnosis rates. These include Hispanic-Americans, African-Americans, Asians, and Pacific Islanders compared with non-Hispanic white populations. The disease is most commonly diagnosed in older adults, with the median age at diagnosis being around the late sixties. Despite advances in detection and treatment, gastric cancer can still be challenging to manage, as it is often diagnosed at an advanced stage.
Survival outcomes depend on factors such as stage at diagnosis, overall health of the patient, and response to treatment. Ongoing research and improved therapeutic approaches continue to focus on early detection and more effective treatment options to improve long-term outcomes for patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing